Ataxin 10 Antikörper

Produktnummer ABIN2856106

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch Ataxin 10 in WB und IHC (p). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Ataxin 10 Antikörper (ABIN2856106)

Target: Ataxin 10 (ATXN10)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ataxin 10 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-Ataxin 10 Antikörper

Kreuzreaktivität: Human

Produktmerkmale: Rabbit Polyclonal antibody to ATXN10 (ataxin 10)
ATXN10 antibody

Aufreinigung: Purified by antigen-affinity chromatography.

Immunogen: Recombinant protein encompassing a sequence within the center region of human ATXN10. The exact sequence is proprietary.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:3000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.

Kommentare:

Positive Control: 293T , A431 , HeLa , HepG2 , U87-MG , SK-N-SH , IMR32 , SK-N-AS

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.78 mg/mL

Buffer: 1XPBS ( pH 7), 1 % BSA, 20 % Glycerol, 0.01 % Thimerosal

Konservierungsmittel: Thimerosal (Merthiolate)

Vorsichtsmaßnahmen: This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.

Details zu Ataxin 10

Target: Ataxin 10 (ATXN10)

Andere Bezeichnung: ataxin 10

Hintergrund: The autosomal dominant cerebellar ataxias (ADCAs) are a clinically and genetically heterogeneous group of disorders characterized by ataxia, dysarthria, dysmetria, and intention tremor. All ADCAs involve some degree of cerebellar dysfunction and a varying degree of signs from other components of the nervous system. A commonly accepted clinical classification (Harding, 1993) divides ADCAs into 3 different groups based on the presence or absence of associated symptoms such as brainstem signs or retinopathy. The presence of pyramidal and extrapyramidal symptoms and ophthalmoplegia makes the diagnosis of ADCA I, the presence of retinopathy points to ADCA II, and the absence of associated signs to ADCA III. Genetic linkage and molecular analyses revealed that ADCAs are genetically heterogeneous even within the various subtypes.[supplied by OMIM]

Molekulargewicht: 53 kDa

Gen-ID: 25814

UniProt: Q9UBB4